Research progress on multimodality treatment for primary tracheal adenoid cystic carcinoma / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
;
(6): 858-861, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-910481
ABSTRACT
Primary tracheal adenoid cystic carcinoma (TACC) is exceedingly rare. Surgical resection is the main treatment for TACC. Whether the operation is radical or not is a key prognostic factor. Postoperative radiotherapy may be suitable to improve the local control rate and long-term survival for patients with positive surgical margin. For unresectable, recurrent and metastatic TACC patients, definitive radiotherapy, chemotherapy and molecular targeted therapies have yielded certain clinical efficacy. The aim of this review is to summarize the research progress on multimodality treatment for TACC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Chinese Journal of Radiation Oncology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS